N-acylethanolamide Prodrugs for Oral Bioavailability
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
N-acylethanolamide compounds face challenges with poor pharmacological properties such as limited bioavailability and low exposure to target sites when administered orally, leading to limitations in dosage and delivery, and potential undesirable side effects.
Innovation Solution
Development of N-acylethanolamide prodrugs conjugated with moieties like phosphate, butyric acid, glycerol, succinate, caprylic acid, and sucrose, which enhance oral bioavailability, cell permeability, stability, and solubility, allowing for effective delivery and reduced first-pass effect.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If N-acylethanolamide compounds are administered orally, then they can be delivered systemically, but their bioavailability is limited and exposure to target sites is low
Solution Approach 1:
The patent employs prodrugs as intermediary compounds that are orally administered and then converted in vivo to the active N-acylethanolamide. The prodrug structure includes a leaving group that enables enzymatic or chemical conversion to release the active compound, thereby improving bioavailability while increasing target site exposure through the mediator's enhanced pharmacokinetic properties
Solution Approach 2:
The patent modifies physical and chemical parameters of the N-acylethanolamide by conjugating it to various moieties (phosphate, butyric acid, glycerol, succinate, caprylic acid, gluconoic acid, eicosapentaeonoic acid, linoleic acid, and sucrose). These parameter changes improve solubility, stability, and membrane permeability, thereby enhancing oral bioavailability and target site delivery
2Reliability
If dosage is increased to overcome poor pharmacological properties, then therapeutic effect may be improved, but side effects increase
Solution Approach 1:
The prodrug acts as a mediator that improves the therapeutic index by enhancing delivery efficiency. At lower doses of the prodrug, equivalent amounts of active compound are delivered more efficiently to target sites, reducing the need for high dosages and thereby minimizing side effects while maintaining therapeutic efficacy
Solution Approach 2:
The patent replaces the direct administration mechanism with a prodrug conversion mechanism. Instead of administering the active compound directly and dealing with its poor pharmacological properties, the system uses a prodrug that is converted in vivo, substituting the direct delivery mechanism with a mediated conversion process that improves efficiency and reduces required dosage
Data Source
AI summary
The present disclosure provides certain N-Acylethanolamide derivatives, and uses relating thereto.